Acer therapeutics announces presentation of hcp urea cycle disorder treatment preference data at the society for inherited metabolic disorders annual meeting and provides olpruva™ program update

Results to be presented from a survey designed to quantify treatment preferences of healthcare providers for urea cycle disorders (ucds)

ACER Ratings Summary

ACER Quant Ranking